PDF(Pubmed)
Abstract：
UNASSIGNED: Incremental healthcare costs attributed to back pain, and characterisation by patient and clinical factors have rarely been documented. This study aimed to assess annual healthcare resource utilisation and costs associated with back pain in primary care.
UNASSIGNED: Using the IQVIA Medical Research Data (IMRD), patients with back pain were identified (study period: 01 January 2006 to 31 December 2015) using diagnostic records and analgesics prescriptions (n = 133,341), and propensity score matched 1:1 to patients without back pain. The annual incremental costs of back pain associated with consultations and prescriptions were estimated and extrapolated to a national level. Sensitivity analysis was conducted by restricting the study population to the most recent diagnosis of back pain. Variations in cost were assessed stratified by gender, age-groups, deprivation, and comorbidity categories.
UNASSIGNED: The mean age was 57 years, and 62% were females in both the case and control groups. The total incremental healthcare costs associated with back pain was £32.5 million in 2015 (£35.9 million in 2020), with per-patient cost of £244 (£265 in 2020) per year. On a national level, this translated to an estimated £3.2 billion (£3.5 billion in 2020). Eighty percent of the costs were attributed to consultations; and female gender, older age, higher deprivation, and higher comorbidity were all associated with increased mean healthcare costs of patients with back pain.
UNASSIGNED: Our findings confirm the substantial healthcare costs attributed to back pain, even with primacy care costs only. The data also revealed significant cost variations across socio-demographic and clinical factors.
UNASSIGNED: Using the IQVIA Medical Research Data (IMRD), patients with back pain were identified (study period: 01 January 2006 to 31 December 2015) using diagnostic records and analgesics prescriptions (n = 133,341), and propensity score matched 1:1 to patients without back pain. The annual incremental costs of back pain associated with consultations and prescriptions were estimated and extrapolated to a national level. Sensitivity analysis was conducted by restricting the study population to the most recent diagnosis of back pain. Variations in cost were assessed stratified by gender, age-groups, deprivation, and comorbidity categories.
UNASSIGNED: The mean age was 57 years, and 62% were females in both the case and control groups. The total incremental healthcare costs associated with back pain was £32.5 million in 2015 (£35.9 million in 2020), with per-patient cost of £244 (£265 in 2020) per year. On a national level, this translated to an estimated £3.2 billion (£3.5 billion in 2020). Eighty percent of the costs were attributed to consultations; and female gender, older age, higher deprivation, and higher comorbidity were all associated with increased mean healthcare costs of patients with back pain.
UNASSIGNED: Our findings confirm the substantial healthcare costs attributed to back pain, even with primacy care costs only. The data also revealed significant cost variations across socio-demographic and clinical factors.
摘要：
■由于背痛导致的医疗费用增加，患者和临床因素的特征很少被记录。本研究旨在评估初级保健中与背痛相关的年度医疗资源利用率和成本。
■使用IQVIA医学研究数据（IMRD），使用诊断记录和镇痛药处方（n=133,341）确定背痛患者（研究期间：2006年1月1日至2015年12月31日），与没有背痛的患者的倾向评分为1：1。估计了与咨询和处方相关的背痛的年度增量成本，并将其推断到国家一级。敏感性分析是通过将研究人群限制在最近的背痛诊断中进行的。成本的变化按性别分层评估，年龄组，剥夺,和合并症类别。
■平均年龄为57岁，在病例组和对照组中，62%为女性。与背痛相关的总增量医疗费用在2015年为3250万英镑（2020年为3590万英镑），每位患者每年的费用为244英镑（2020年为265英镑）。在国家层面,这相当于估计32亿英镑(2020年为35亿英镑)。80%的费用归因于咨询；女性，年龄较大,更高的剥夺，和较高的合并症均与背痛患者的平均医疗费用增加相关.
■我们的研究结果证实了背痛导致的大量医疗费用，即使只有首要护理费用。数据还显示，社会人口统计学和临床因素之间的成本差异很大。
■使用IQVIA医学研究数据（IMRD），使用诊断记录和镇痛药处方（n=133,341）确定背痛患者（研究期间：2006年1月1日至2015年12月31日），与没有背痛的患者的倾向评分为1：1。估计了与咨询和处方相关的背痛的年度增量成本，并将其推断到国家一级。敏感性分析是通过将研究人群限制在最近的背痛诊断中进行的。成本的变化按性别分层评估，年龄组，剥夺,和合并症类别。
■平均年龄为57岁，在病例组和对照组中，62%为女性。与背痛相关的总增量医疗费用在2015年为3250万英镑（2020年为3590万英镑），每位患者每年的费用为244英镑（2020年为265英镑）。在国家层面,这相当于估计32亿英镑(2020年为35亿英镑)。80%的费用归因于咨询；女性，年龄较大,更高的剥夺，和较高的合并症均与背痛患者的平均医疗费用增加相关.
■我们的研究结果证实了背痛导致的大量医疗费用，即使只有首要护理费用。数据还显示，社会人口统计学和临床因素之间的成本差异很大。
